All these results seem to indicate that an increased TF-FVIIa interaction, marked by high FVIIa-AT levels, may be a common molecular mechanism underlying unfavorable outcomes in different clinical settings, from cardiovascular disease to cancer. The gene discussed is TF; the disease is cancer.